PASSAMONTI, FRANCESCO

PASSAMONTI, FRANCESCO  

Dipartimento di Oncologia ed Emato-Oncologia  

Mostra records
Risultati 1 - 20 di 162 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 2024 Passamonti, FrancescoGuidetti, Anna + Article (author) -
Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis 2024 Lazzaroni, FrancescaMatera, AntonioMarella, AlessioMaeda, AkihiroCastellano, GiancarloMarchetti, AlfredoFabris, SoniaSilvestris, IlariaRonchetti, DomenicaLonati, SilviaFabbiano, GiuseppinaTraini, ValentinaTaiana, ElisaDe Magistris, ClaudioScopetti, MargheritaBarbieri, MarziaPettine, LoredanaNeri, AntoninoPassamonti, FrancescoLionetti, MartaBolli, Niccolò + Article (author) -
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group 2024 Passamonti, FrancescoRambaldi, Alessandro + Article (author) -
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey 2024 Farina, FrancescaFracchiolla, Nicola SPassamonti, FrancescoGuidetti, Anna + Article (author) -
Circulating biomarkers in familial cerebral cavernous malformation 2024 Lanfranconi, SilviaTassi, LauraLeone, RobertoBolli, NiccoloPassamonti, Francesco + Article (author) -
The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers 2024 Ronchetti, DomenicaTraini, ValentinaSilvestris, IlariaPassamonti, FrancescoBolli, NiccoloTaiana, Elisa + Article (author) -
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial 2024 Passamonti, Francesco + Article (author) -
Natural history of chronic idiopathic neutropenia of the adult 2024 Fattizzo, BrunoBosi, AlessandroSorrenti, MicheleMurgia, DavideCroci, Giorgio AlbertoPassamonti, Francesco + Article (author) -
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2 2024 Passamonti, Francesco + Article (author) -
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib 2024 Passamonti, Francesco + Article (author) -
Using real-world evidence in haematology 2024 Passamonti, Francesco + Article (author) -
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases 2024 Cattaneo, DanieleMarchetti, AlfredoGalli, NicoleLionetti, MartaGianelli, UmbertoPassamonti, FrancescoBolli, Niccolò + Article (author) -
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib 2024 Cattaneo, DanieleGalli, NicoleFidanza, Cecilia AnnaPassamonti, Francesco + Article (author) -
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries 2024 Passamonti, FrancescoCorradini, Paolo + Article (author) -
Prognostic and Predictive Models in Myelofibrosis 2024 Cattaneo, DanieleVersino, FrancescoPassamonti, Francesco + Article (author) -
Early treatment for COVID-19 in patients with haematological malignancies: Much more than a recommendation! 2023 Passamonti, FrancescoBandera, Alessandra Article (author) -
Incidence of blast phase in myelofibrosis according to anemia severity 2023 Passamonti, Francesco + Article (author) -
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 2023 Passamonti, Francesco + Article (author) -
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis 2023 Francesco Passamonti + Article (author) -
SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment? 2023 Passamonti, Francesco + Article (author) -